Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
229 studies found for:    nash
Show Display Options
RSS Create an RSS feed from your search for:
nash
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Condition: Non-Alcoholic Steatohepatitis
Intervention:
2 Terminated
Has Results
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Steatohepatitis (NASH);   Hepatic Steatosis
Interventions: Drug: Omega-3-acid ethyl esters (Lovaza);   Drug: Placebo
3 Active, not recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
4 Completed The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: obeticholic acid;   Drug: placebo
5 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
6 Recruiting Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GR-MD-02;   Drug: Placebo
7 Completed
Has Results
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Conditions: Nonalcoholic Steatohepatitis;   Liver Diseases
Interventions: Drug: Pentoxifylline;   Drug: Placebo
8 Active, not recruiting Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
9 Recruiting Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NASH
Condition: Nonalcoholic Steatohepatitis (NASH)
Intervention: Drug: EZ-Urso combination therapy
10 Completed Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Condition: Non-Alcoholic Steatohepatitis(NASH)
Interventions: Drug: Active treatment;   Drug: Placebo
11 Active, not recruiting Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
12 Completed Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
Conditions: Hepatic Cirrhosis;   Nonalcoholic Steatohepatitis
Intervention: Drug: NRL972
13 Completed Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions: Non-alcoholic Steatohepatitis;   Fatty Liver
Interventions: Drug: Omega 3 Fish Oil supplements;   Drug: Placebo
14 Completed Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Intervention: Drug: TRO19622
15 Terminated An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
Condition: Fatty Liver
Interventions: Drug: rimonabant (SR141716);   Drug: Placebo
16 Terminated An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
Condition: Fatty Liver
Interventions: Drug: rimonabant (SR141716);   Drug: Placebo
17 Recruiting Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
Condition: NASH Related Cirrhosis
Interventions: Drug: Metformin;   Drug: Insulin
18 Completed The Role of Leptin Receptors in NASH
Conditions: Nonalcoholic Steatohepatitis;   Metabolic Syndrome
Intervention: Other: no interventions, only regular blood-draw
19 Recruiting Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
Condition: Obesity
Intervention: Drug: Metformin
20 Not yet recruiting A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
Condition: Fatty Liver
Intervention: Drug: Aramchol

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years